Thank you for subscribing!

The Science of Better Pharmaceutical Delivery

Though improved delivery of bioactive compounds, bioavailability is big business


What if you could take a pill and feel the effects almost immediately?

From prescription medications to recreational compounds, the potential market for this kind of technology is huge. But what most don’t realize is that this technology is already here.

Lexaria Bioscience (Nasdaq:LEXX) has developed a technology that makes orally and topically administered drugs significantly more bioavailable, and reduces the onset time from hours to mere minutes.

DehydraTECH™, Lexaria’s patented drug delivery technology is shaping up to be a real game changer.

Tested and proven in the lab and in the market, the consensus is clear: DehydraTECH™ works. It increases the bioavailability of fat-soluble drugs and molecules by as much as 2 to 10 times, and with up to 10 times faster onset.

The technology also masks unpleasant tastes and odors, can bypass the liver, and can reduce harmful side effects by allowing smaller doses with the same level of effectiveness.


Quick Facts for Investors

Established bioscience leader

Lexaria has been developing its proprietary DehydraTECH™ technology since 2014 and has the team, the expertise, and the results to match.

Increased Bio-absorption

Lexaria’s proprietary process not only makes fat-soluble molecules more bioavailable when taken orally, it also delivers these useful compounds to the bloodstream and brain tissue to have the greatest effect.

Faster onset

Instead of waiting hours, drugs and supplements made with DehydraTECH™ can take effect in as little as 2 to 4 minutes.

Proven efficacy 

Laboratory studies and the market have shown again and again that DehydraTECH™ is safe, significantly faster and more effective than conventional formulations, and has greater absorption of the intended molecules. And in July, 2022, Lexaria submitted its briefing book to the US Food and Drug Administration (FDA) regarding Lexaria’s DehydraTECH-CBD for the treatment of hypertension and at the same time its 27th worldwide patent was granted. 

Broad applications

DehydraTECH™ has been successfully applied to various legal recreational compounds, antivirals, sildenafil and more. There are 27 granted patents and over 50 more patent-pending applications for phosphodiesterase inhibitors, estrogen, testosterone, antiviral drugs, hypertension treatments, and more, as more industries see the incredible potential of this game changing technology.

Trillion dollar licensing opportunity

At the end of 2020, the pharmaceutical market was valued at approximately $1.27 trillion. At the same time, the global supplementation market was valued at over $140.3 billion and nicotine replacement is expected to be a $147.9 billion market by 2028.2 Through improved bioavailability and decreased onset time DehydraTECH™ represents huge multiple licensing opportunities for Lexaria and their investors. On top of this, Lexaria has already secured a licensing agreement with the largest tobacco company in the country for DehydraTECH, giving investors exposure to this $853 billion industry. Combined, this represents well over $2 trillion of potential addressable market share.

The company has recently announced licensing deals bringing DehydraTECH™ to the European, Japanese, Australian, South African, and New Zealand markets, with more deals expected soon.

Precision Delivery of Active Pharmaceutical Ingredients

With unsurpassed ease and simplicity of administration, it’s no surprise that a large portion of drugs come in pill or capsule form. We’ve all swallowed our share of pills, but most people don’t give much thought to what happens once it enters the stomach.

Through the process of digestion, active ingredients are eventually absorbed to perform their desired function in the body. But if you’ve ever taken a pill, you’ve also likely noticed that the active ingredients can take a while to take effect, often as long as several hours. What you may not realize, is that for some active pharmaceutical ingredients (“APIs”), as little as 2% of the drug actually reaches your bloodstream! That’s right, sometimes 98% is wasted.

There are a variety of reasons for this, and we’ll spare you the complicated scientific explanation today, but in the pharmaceutical and consumer product industries, this phenomenon has a name: bioavailability.

What good is a pill if the active ingredients aren’t efficiently absorbed into the body? How beneficial is a medication when it comes along with unpleasant side effects at the required effective dose? Increasing bioavailability solves all of this, and that’s exactly what Lexaria’s proprietary DehydraTECH™ technology delivers.

By combining the API with certain fatty acids, infusing the mixture into a substrate material, and then using a patented dehydration synthesis processing to associate the payload and fatty acids together at a molecular level, Lexaria can dramatically improve the bioavailability of a wide range of APIs.

In addition to increasing bioavailability and decreasing onset time, DehydraTECH also allows manufacturers to, at times, bypass liver first-pass liver metabolization, which can enable some APIs to work far better.


Hepatic Transport

For certain preparations to work best, they need to be processed first by the liver before entering the bloodstream. When this is desired, Lexaria uses medium chain fatty acids in the DehydraTECH process. Medium chain fatty acids are directed to and processed in the liver, so combining them with drugs or supplement payloads delivers these molecules directly to the liver for processing.

Lymphatic Transport

But – and this is where DehydraTECH’s versatility outshines the competition – many other APIs work better if the liver could somehow be bypassed, allowing the drug to enter the bloodstream without being altered by the liver. This is called bypassing first-pass liver metabolization, and Lexaria believes they have figured out how to achieve this remarkable feat. To accomplish this, Lexaria uses specific long chain fatty acids in the patented DehydraTECH formulations and process. Long chain fatty acids are absorbed by the lymphatic system and thereby bypass initial processing in the liver. This results in extremely rapid onset and the ability to deliver certain APIs to the bloodstream in their original form, unaltered by the liver. This can be ideal for pain relief or as an anti-seizure medication, and for other immediate medical needs.


Market Dominance Through Licensing

As you’ve seen by now, the market potential for DehydraTECH is huge and growing every day as new applications are discovered. Lexaria has created something that greatly improves the effectiveness, delivery, and rapidity of a wide variety of medications and supplements and the market is taking notice.

Through their products, Lexaria has already proven, time and time again, that DehydraTECH works. The market has confirmed this, through the generation of licensing revenues that has now begun.

But rather than keeping the power of DehydraTECH to itself, Lexaria has made the smart decision to pursue licensing deals with big pharma, companies developing reduced risk nicotine products, CBD, supplement producers, and more. If there’s a molecule that DehydraTECH can make more effective, Lexaria wants producers to have access to the technology.

That’s why, as exciting as current successes and revenues have been for Lexaria, smart investors are most excited about the potential revenue growth that will come with additional DehydraTECH licensing agreements and opportunities.

If you are not familiar with how licensing works in the pharma industry, and to show the craftiness behind Lexaria’s strategy, did you know that companies like Lexaria can generate hundreds of millions in revenues BEFORE a drug or product ever hits the marketplace? Some biotech investors know that it can take many years to get a drug approved and into the marketplace. But Lexaria’s licensing strategy can earn the company millions or even up to hundreds of millions in revenues through so-called milestone payments.

Milestone payments can be earned when a new drug candidate has been licensed by a major pharmaceutical partner and “graduates” through the FDA Phase I, Phase II, and Phase III regulatory process. As risks are removed, the company that has supplied the underlying technology which in this case is Lexaria, often receive these milestone payments, similar to the $30 million clinical milestone payment Janssen Pharmaceuticals Inc. recently paid to MeiraGTx, which reflects the growing likelihood that their technology is more likely to enter the market.

For a growing company like Lexaria, being able to receive milestone payments is a path towards faster growth or more R&D WITHOUT having to issue any more dilutive equity or take on any burdensome debt. It’s a brilliant strategy. Let’s take a look at how and where Lexaria is taking advantage of this strategy and growing a global presence in the proces with various DehydraTECH applications:


Medical Cannabis in Europe

Lexaria has granted a non-exclusive license to produce DehydraTECH™ medical cannabis products for the European market to Valcon Medical. Valcon Medical is a European contract manufacturing organization, specialized in the manufacturing of medical cannabis extracts for the European Union and the UK.

“We are very excited to have licensed Lexaria’s DehydraTECH technology for what we expect will be rapid growth across the European markets,” said Pete Patterson, CEO of Valcon Medical. “As Valcon continues to build out its manufacturing capabilities we are developing new IP and partnering with industry leaders. Lexaria has developed and patented an incredible technology which will benefit medical cannabis patients with enhanced bioavailability with a quicker effect onset. Backed by substantial clinical efficacy studies, Valcon will bridge the extensive work that Lexaria has done in the US, over to Europe.”


Expanding Production Capabilities in the U.S.

In the U.S., Lexaria’s most recent licensing opportunity came in the form of a two-part agreement with Georgia-based Bevnology. The agreement first expands the manufacturing capabilities for Lexaria, capitalizing on Bevnology’s production capabilities and making DehydraTECH available to an expanding list of Lexaria corporate clients. Second, the agreement grants a commercial license to offer DehydraTECH products with active ingredients derived from hemp including cannabidiol (“CBD”) under BevNology and partnered brands.

Bevnology is a beverage development and advisory company with plenty of expertise in steering the commercialization of beverage products, whether they are for new or established brands. Translation: they bring a lot of relationships and potential product opportunities in which Lexaria’s state-of-the-art technology can be marketed and used.  Lexaria will be receiving royalties from Bevnology, creating a new and exciting revenue stream for the growing company.

“These agreements build on a long standing and very successful product development consulting relationship between Lexaria and the expert scientists and personnel at BevNology,” said Chris Bunka, CEO of Lexaria. “BevNology’s formulation and production capabilities are class leading  and we are confident that our new relationship with our trusted partner will propel new and exciting growth opportunities for both companies.”


A Global CBD Opportunity

California-based Cannadips has taken the age-old chewing tobacco concept and given it some modern innovation…without the health hazards. Their CBD pouches are a tobacco-free and nicotine-free dip alternative delivering CBD with the aid of Lexaria’s DehydraTECH.

Cannadips are sold in 6,500 stores across the United States along with the company’s direct-to-consumer sales structure, and are expanding manufacturing agreements to include Europe, Japan, and South Africa, giving DehydraTECH a truly impressive global footprint.

“We are delighted with the expansion of the Cannadips brand outside of the USA,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “We continue to work with the Cannadips team on the infusion of exciting new formulations to meet the needs of adult consumers’ changing preferences and will endeavour to always remain one step ahead of the competition.”


Wellness Overseas

The company also recently announced licensing deals with Premier Wellness Science Co., Ltd. in Japan, and with AnodGen Bioceuticals to bring DehydraTECH to the European, Australian and New Zealand markets, with Lexaria receiving a royalty on all sales.

As we’ve mentioned, the pharmaceutical industry is already valued at well over $1 trillion, and the supplement industry is also growing fast. DehydraTECH makes these beneficial molecules and medications more bioavailable, decreases onset time, masks unwanted flavors and odors, and in many cases, increases effectiveness and reduces side effects. We expect adoption and licensing agreements to explode in the coming years as more and more manufacturers become aware of the benefits DehydraTECH can provide.

Summary For Investors

Lexaria has created something unique with DehydraTECH. Market applications are vast with pharmaceuticals, antivirals, legal recreational compounds, and more.

Tested and proven in the lab and in the market, DehydraTECH works, and formulations made with this method are already in high demand from both consumers and drug and supplement manufacturers.

While one division is already bringing in revenue for Lexaria, the real potential of DehydraTECH, especially for investors who get in now, lies in licensing opportunities and milestone payments. The pharmaceutical market is valued at well over $1 trillion, and a significant portion of big pharma’s drug catalog stands to benefit from the increased bioavailability, reduced onset time, and precision targeting that DehydraTECH provides. The company has filed with the FDA to formally initiate communications FDA regarding development of Lexaria’s DehydraTECH-CBD for the treatment of hypertension.

Tobacco and nicotine is another $853 billion market Lexaria is already breaking into in the form of licensing agreements for oral nicotine delivery. Reduced risk products are expected to be a major focus for the tobacco industry as people turn away from cigarettes, and DehydraTECH is proving to be more effective than anything else on the market.

Recent deals with Valcon Medical and AnodGen Bioceuticals is set to bring DehydraTECH medical cannabis products to the European, Australian and New Zealand markets, further expanding the company’s reach in this growing space, and a similar deal with Premier Wellness Science Co., Ltd. is set to bring DehydraTECH-enabled products to Japan. Lexaria will receive royalty payments on all DehydraTECH sales under these deals.

The bottom line is, DehydraTECH works, and the market is beginning to take notice. As new licensing agreements and use cases continue to stack up, early investors are set to win big with Lexaria Bioscience. Pharmaceuticals, supplements, and nicotine represent well over $2 trillion of market share, and DehydraTECH has the potential to revolutionize all of these industries.

Far from the usual boring investments, Lexaria Bioscience just might be one of the best kept secrets in the market today.

Press Releases






For more information, click here



Who are we and what do we do? We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”). How is the Information published? We publish the Information on our Website, in newsletters, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer or third party paying us. Our publication of the Information is known as a “Campaign”. Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. How is a potential investor impacted if he receives the Information later than other investors? Typically, the trading volume and price of a Profiled Issuer’s securities increases after the Information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer increased trading losses if he purchases the securities of a Profiled Issuer. What will happen to the shares that we hold during the Campaign? We will sell the shares we hold while we tell investors to purchase during the Campaign. What will happen when the Campaign ends? Most, if not all, of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profiled Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment. Why do we publish only favorable Information? We only publish favorable information because we are compensated to publish only favorable information. Why don’t we publish negative Information? We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information. Is the Information complete, accurate, truthful or reliable? No. The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. What we do not do? We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities. Where does the Information come from? The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources. If we say we make “stock picks,” are those picks our own? No, they are not. We are compensated to advertise the securities we are told to advertise. What will happen if an investor relies on the Information? If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision. Who pays us to publish the Information? The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities. The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”. What warranties do we make about the Information? None. We make no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation. What we are not. We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
  • An independent adviser or consultant;
  • A fortune teller;
  • An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
  • A broker-dealer or an individual acting in the capacity of a registered representative or broker;
  • A stock picker;
  • A securities trading expert;
  • A securities researcher or analyst;
  • A financial planner or one who engages in financial planning;
  • A provider of stock recommendations;
  • A provider of advice about buy, sell or hold recommendations as to specific securities; or
  • An agent offering or securities for sale or soliciting their purchase.
Are risks in this disclaimer the only risks investors should be aware of? No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer. What conflicts of interest do we have in publishing the Information? We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. What will happen to the shares that we hold during the Campaign? We will sell the shares we hold while we tell investors to purchase. Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
  • We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
  • We do not publish any negative information whatsoever about the Profiled Issuers;
  • We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
  • A short time after we acquire a Profiled Issuer’s securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
  • Parties holding a Profiled Issuer’s securities, including those who engage our services and/or compensate us, will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
Who is responsible if an investor relies on the Information? The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions or errors in the Information, and we are not responsible for actions taken by any person who relies upon the Information. What do we urge potential investors to do? We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, or other available public sources. Why is this Disclaimer being provided? We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell our own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns. What are other risks that investors should be aware of? Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
  • We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
  • If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
  • The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
  • The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
  • You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
  • We or other stock promoters may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
  • We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
  • When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
  • The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
  • If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement Action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
  • We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and fail to disclose their compensation to you.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at, or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at and You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at What we were paid to advertise the Profiled Issuers. The details of our compensation and the period of the Campaign is set forth below.
  • Name of Issuer & Ticker Symbol - Lexaria Bioscience Corp. (LEXX)
  • Amount & Form of Compensation - $1,200,000 in Restricted Common Stock
  • Who Paid for the Campaign & Position with Company if any - Lexaria Bioscience Corp. (LEXX)
  • Period of Campaign - 12/14/2021 - 12/14/2022
What securities of the Profiled Issuers do we hold? The positions we hold of the Profiled Issuer are set forth below. We plan to sell these securities during the Campaign.
  • Name of Issuer & Ticker Symbol - Lexaria Bioscience Corp. (LEXX)
  • Number of Shares We or our Affiliates Hold - 224,299
  • Price We Paid Per Share - $0
  • Date Issued - 12/14/2021

Related Post

Register to Download the Presentation

Go to website
Go to top